echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > vadadustat achieved positive results in a number of Phase 3 trials for patients with renal anemia

    vadadustat achieved positive results in a number of Phase 3 trials for patients with renal anemia

    • Last Update: 2020-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    March 13, Akebia Therapeutics(http://announced that the company's development of vadadustat, developed jointly with Mitsubishi MitsubishiPharmaceutical(http://Corporation (MTPC), had achieved positive results in theof a number of phase 3trial
    s (http:// for patients with renal anemiaVadadustat
    Vadadustat is an oral hypoxic-inducing factor protalysine inhibitor (HIF-PHI)MTPC is expected to submit an application fornew drug(http://in Japan later this yearVadadustat's role is to simulate the body's physiological response to hypoxia at high altitudesAt high altitudes, the body's response to the scarcity of oxygen is to increase hIF production HIF regulates the mobilization of iron and the production of EPO to stimulate the production of red blood cells, thereby improving oxygen transport if approved, Vadadustat will provide patients with an oral treatment option and could become a new standard treatment for patients with renal anemia   In a randomized, open labeled, active control Phase 3 clinical trial called J01, 304 non-dialysis-dependent renal anemia patients received vadadustat and an ESA treatment The results showed that after 24 weeks of treatment, the study reached its main endpoint Hemoglobin levels in the Vadadustat patient group met non-performance standards compared to the active control group In the J03 randomized double-blind, active control Phase 3 clinical trials treating patients with dialysis-dependent renal anemia, vadadustat also reached the main end of the trial and reached the non-adverse standard compared to ESA   About renal anemia
    renal anemia is a common complication of chronic kidney disease (CKD) The kidneys are an important organ for the production of red blood cell oxytocin (EPO), which stimulates the production of red blood cells in the bone marrow renal anemia is due to decreased renal function, on the one hand, the production of EPO decreased, on the other hand, the kidneys of anemia caused by hypoxia stimulation can not produce an adequate response
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.